Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial

Next Previous
X
Search
Trial Profile

Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Acronyms HEAT

    • Most Recent Events

    • 04 Jul 2022 Results comparing the treatment changes between enzalutamide and abiraterone acetate plus prednisone in hormones of the pituitary gonadal axis, presented at the 37th Congress of the European Association of Urology.
    • 13 Jun 2022 Results evaluating Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone, published in the European Journal of Cancer
    • 05 Mar 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top